Chemotherapy-induced nausea and vomiting (CINV) prophylaxis is governed by an emetogenic-risk classification system that stratifies chemotherapy regimens into high, moderate, and low categories, with prophylactic drug combinations (steroid, NK1-receptor antagonist, 5-HT3-receptor antagonist, and olanzapine) escalating in number according to risk tier. The framework further accounts for delayed emesis requiring multi-day coverage beyond the day of administration, and for combination regimens whose emetogenic risk exceeds that of their constituent agents given individually. This belongs to supportive/palliative oncology pharmacology, situated within evidence-based clinical guideline development that synthesizes trial data into risk-stratified prophylactic protocols.
Chemotherapy-induced nausea and vomiting (CINV) prophylaxis is governed by an emetogenic-risk classification system that stratifies chemotherapy regimens into high, moderate, and low categories, with…